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AbstrAct
Seckel Syndrome (SS) and Primary Microcephaly (MCPH) are disorders exhibiting 
marked microcephaly with a head circumference less than three standard deviations 
below the mean. ATR‑Seckel Syndrome is conferred by mutations in ataxia and telangiec‑
tasia and Rad3 related (ATR), a kinase that activates a DNA damage signalling response. 
Cell lines from additional SS patients, who are normal for ATR, show defective ATR 
signalling, suggesting that they carry mutations in other components of the ATR pathway. 
Primary Microcephaly is distinct from SS since patients display solely microcephaly 
without accompanying marked growth delay. MCPH1, the first Primary Microcephaly 
causative gene identified, encodes three BRCT domains, similar to other damage 
response proteins. Recent studies employing MCPH1 siRNA or exploiting cell lines from 
MCPH1 patients have shown that MCPH1 functions in the ATR‑dependent DNA damage 
response pathway. Additionally, MCPH1 has a function in the regulation of mitotic entry 
that is ATR‑independent and confers a characteristic phenotype of premature chromosome 
condensation. Recent studies will be reviewed and their relationship to the aetiology of 
microcephaly discussed.
brAin DevelOPMent AnD MicrOcePhAly
The human brain develops from a swelling at the rostral end of the neural tube. Rapid 
and sustained cellular proliferation during fetal development is required to generate the 
brain, and especially the cerebral cortex. Cerebral cortical surface area has increased over 
a thousand fold during mammalian evolution, and consequently in higher mammals to 
accomodate the brain within the skull, the cerebral cortex must fold to assume an invagi-
nated, convoluted appearence with gyri and sulci.
Microcephaly is a clinical term denoting reduced head size, defined as reduced head 
circumference greater than 3 standard deviations below the mean (-3 s.d.). Reduced head 
size reflects an underlying reduction in brain volume (Fig. 1A), and not surprisingly has 
multiple aetiologies, both genetic (nonsyndromic, syndromic or chromosomal) and envi-
ronmental (eg. perinatal asphyxia, and intrauterine infection). Autosomal recessive Primary 
Microcephaly (MCPH, OMIM251200) is a form of microcephaly in which patients 
exhibit solely a reduced cerebral cortex without other developmental abnormalities or 
neurological deficits (aside from mental retardation).1 MCPH brains, although very small 
(typically -4 to -12 s.d.), exhibit normal cortical architecture suggesting that microcephaly 
is a consequence of reduced cell number either as a result of reduced neuroprogenitor divi-
sion or increased apoptosis during neurogenesis (Table 2).
Microcephaly is also a common feature observed in genetic disorders that additionally 
confer growth delay (e.g., Phenylketonuria, Down’s syndrome, Di�eorge syndrome). A      
striking example is Seckel Syndrome (SS) (OMIM210600), where microcephaly and growth 
delay is characteristic and marked. Dysmorphic facial features (sloping forehead, prominent 
nose, small chin) are also observed in such patients explaining the original description of 
‘Bird-headed dwarfism’ (Fig. 1A).2 To date, the only causative genetic defect identified in SS is 
a hypomorphic mutation in Ataxia telangiectasia and Rad3-related (ATR), which encodes a 
protein that plays a central role in the response to DNA damage.3 Furthermore, cell lines from 
additional non-ATR mutated SS patients display defects in ATR-dependent damage 
responses.4 Nijmegen Breakage Syndrome (NBS) (OMIM251260) patients also display 
Seckel-like features including microcephaly, growth delay and similar facial features, and 
Nbs1, the defective protein, functions in the response to DNA damage (Table 2). Together 
these findings provide evidence for a link between defective DNA damage response signalling 
and microcephaly.
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Currently six MCPH loci and four genes conferring Primary 
Microcephaly have been identified (Table 1).5 Microcephalin 
(MCPH1) was the first causative Primary Microcephaly gene 
identified.5,6 It was subsequently independently identified as 
“Brit1” (BRCT-inhibitor of hTERT expression) in a screen 
for genes influencing telomerase expression.7 Although the 
MCPH1 disorder is classified as Primary Microcephaly, 
patients can display growth retardation, feature also seen in  SS 
and NBS patients. MCPH1 encompasses three BRCT motifs, 
with N-terminal and tandem C-terminal locations (Fig. 1B). 
BRCT motifs are commonly found in DNA damage response 
proteins, particularly those functioning as mediators in the 
signalling response providing provocative although circum-
stantial evidence that MCPH1 might function in a DNA 
damage response pathway.6
DnA DAMAge resPOnse signAlling
Two DNA damage response signalling pathways have been 
described, both of which are regulated by related phosphoinositol 
3-kinase-like kinases (PIKKs).8 Ataxia telangiectasia mutated (ATM), 
the kinase defective in the disorder ataxia telangiectasia (A-T), is 
activated by DNA double strand breaks (DSBs), whereas ATR 
responds to single stranded DNA regions that can arise at stalled 
replication forks or during the processing of bulky lesions such as a 
UV photodimer. Both kinases have partner proteins which facilitate 
lesion targeting; Nbs1 promotes ATM activation and ATR interacting 
protein (ATRIP) is required for ATR recruitment to damage sites.9-10 
In the present context, it is relevant that Nbs1 also functions in the 
ATR signalling response.11 Kinase activation promotes phosphor-
ylation of the histone variant, H2AX, at the site of damage, which 
faciliates the recruitment of mediator proteins, including 53BP1, 
MDC1 and Brca1, giving rise to characteristic ionising radiation 
(IR)-induced foci (IRIF).12 ATM and ATR phosphorylate many of 
the same substrates, thereby initiating overlapping damage responses 
although recent evidence suggests that there is specificity as well as 
overlap in substrate phosphorylation. Of significance, ATM appears 
to preferentially target the transducer kinase, Chk2, whereas ATR 
has a preference for Chk1.10 Finally, via phosphorylation of effector 
proteins either directly or indirectly by ATM/ATR, DNA damage 
response signalling leads to cell cycle checkpoint arrest and/or the 
onset of apoptosis. Interestingly, whilst ATR is essential, ATM is 
nonessential.13 Moreover, in distinction to ATR-SS, A-T patients 
display progressive ataxia, immunodeficiency, pronounced cancer 
predisposition and do not display microcephaly (Tables 1 and 2).
stuDies On McPh1 FunctiOn
Three routes have been traversed to examine MCPH1 involve-
ment in the DNA damage response. Firstly, using cell biology, 
HA tagged- and endogenous MCPH1 was shown to colocalise 
with MDC1 and g-H2AX IRIF in response to IR, suggesting that 
MCPH1 localises to the sites of DNA damage.14-16 Secondly, siRNA 
knock down of MCPH1 has been employed to examine the impact 
of reduced MCPH1 function on the response to DNA damage. 
Strikingly, knock down of MCPH1 was accompanied by co-knock 
down at the transcriptional level of Brca1 and Chk1 via an unknown 
mechanism.14,15 MCPH1 knock down also impacted upon MDC1, 
53BP1 and ATM foci formation although it did not impair ATM 
activation, monitored by ATM-S1981 phosphorylation, nor Chk2 
phosphorylation or protein levels.14,16 MCPH1 siRNA also caused radio- 
resistant DNA synthesis, a characteristic phenotype of A-T cells due 
to impaired IR-induced intra-S-phase checkpoint arrest, reduced 
�2/M checkpoint arrest after IR and increased sensitivity to IR. 
Despite the fact that Chk2 phosphorylation was not affected by 
MCPH1 siRNA, Nbs1 phosphorylation after IR was reduced.14,15 
Taken together, it was concluded that MCPH1 is required for the 
formation of damage response foci and additionally functions to 
transcriptionally regulate Chk1 and Brca1, hence acting as a crucial 
DNA damage regulator. Interestingly, changes in MCPH1 expression 
were found in a number of tumour cell lines and in primary tumour 
material, suggesting that MCPH1 functions as a tumour suppressor 
gene.16
The third, distinct approach to examine MCPH1 function 
involved an analysis of cell lines derived from MCPH1 patients. 
Initial studies demonstrated that MCPH1 patient lymphocytes 
and derived cell lines display a characteristic phenotype of elevated 
numbers of cells with prematurely condensed chromosomes (PCCs) 
(see below for further details).17 No evidence of a damage response 
defect to IR was observed, however.17 More recently, we focused on 
an analysis of the ATR signalling response in MCPH1 defective cells 
due to the overlapping clinical features of MCPH1 deficiency and 
ATR-SS.4 These studies revealed a downstream role for MCPH1 in 
the ATR-signalling response that is distinct to the findings described 
using siRNA. Activation of ATR and phosphorylation of key 
ATR-substrates, including Nbs1, following replication fork stalling 
were normal. Additionally, MCPH1 cells recover from replication 
fork stalling normally in contrast to an ATR-SS cell line. Strikingly, 
however, MCPH1 cells were unable to effect ATR-dependent �2/M 
checkpoint arrest. Additionally, elevated nuclear fragmentation after 
replication fork stalling was observed as well as the appearance of 
supernumerary mitotic centrosomes, two further features common 
with ATR-SS cells. In contrast to studies employing siRNA, MCPH1 
patient cells expressed normal protein levels of Chk1 and Brca1, and 
Chk1 was phosphorylated normally after DNA damage. Indeed, two 
independent Chk1 functions occur normally in MCPH1 cell lines 
(53BP1 foci formation following replication stalling and replication 
fork stability). These findings, therefore argue that MCPH1 func-
tions in the ATR-dependent DNA damage response pathway in a 
manner that is independent of Chk1 or Brca1 regulation. MCPH1 
cells showed impaired degradation of Cdc25A, identical to that 
observed in ATR-Seckel cells, both in unperturbed cell growth as well 
as following UV irradiation. These findings suggest that MCPH1 
acts to regulate Cdc25A. Interestingly, MCPH1 was also found to 
Figure 1. (A) A pictorial representation of microcephaly. The line drawings show a 
normal individual (i) alongside a microcephalic individual (ii). Note that the reduced 
occipitofrontal circumference (dipicted by the dashed line) of the microcephalic 
individual results in a sloping forehead and apparent protrusion of the face, as 
originally noted by Seckel.2 (B). Schematic representation of MCPH1 protein showing 
the relative locations of the three BRCT domains.
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interact with Chk1.4 The regulation of Cdc25A activity and stability 
is still poorly understood. However, there is clear evidence that Chk1 
phosphorylates Cdc25A at multiple sites that can regulate both its 
activity and ubiquitin-dependent degradation.18
Importantly, the analysis of MCPH1 cell lines has revealed an 
impact of MCPH1 deficiency that has proved to be distinct to 
its impact on the DNA damage response. As mentioned above, 
MCPH1 cells show a striking elevation in prophase-like PCC 
cells. This phenotype is due to MCPH1 deficient cells condensing 
their chromosomes within an intact nuclear envelope during �2 
and also delaying decondensation post mitosis, strongly suggesting 
that loss of MCPH1 causes aberrant regulation of chromosome 
condensation.17,19 The PCC phenotype is not observed in A-T nor 
in ATR-SS cells suggesting that it is not a consequence of a defec-
tive DNA damage response.4 Strikingly, we observed that the levels 
of inhibitory Tyr15 phosphorylated Cdk1 (pY15-Cdk1) observed 
in cells released following synchronisation at the �1/S boundary 
decreased rapidly in MCPH1 cell lines compared to control cells 
in parallel to elevated PCC formation.4 Moreover, normal �2 cells 
were not observed in MCPH1 cell lines but instead cells with PCCs 
were �2-like, since they did not express phospho-Ser10-histone 
H3, retained an intact nuclear envelope but lacked detectable 
pY15-Cdk1. Taken together, these findings suggest that MCPH1 has 
an ATR-independent role in regulating mitotic entry by maintaining 
inhibitory Cdk1 phosphorylation. Interestingly, another recent 
study using MCPH1 patient cell lines, showed that condensin II was 
localised to the nucleus in PCC cells and in some cases was bound to 
the central chromosomal axis, even though condensin I was still in 
the cytoplasm.20 In contrast, condensin II is cytoplasmically localised 
in normal �2 cells. Although nuclear localisation in some cells can be 
observed, its enrichment in the chromatid axis is rare. This suggests 
that a consequence of MCPH1 deficiency is the premature binding 
of condensin II to chromatin. Furthermore, siRNA depletion of 
condensin II subunits was able to alleviate the PCC phenotype as 
well as the delayed post-mitotic decondensation phenotype. The 
PCC phenotype was also observed in Hela, lymphoblastoid cell lines 
and U20S cells after MCPH1 siRNA, and in Hela cells this was 
prevented by simultaneous depletion of condensin II. Knock down 
of condensin I did not impact upon the PCC phenotype.
recOnciling the MultiPle iMPActs OF McPh1 DeFiciency
Taken together, these findings suggest that MCPH1 deficiency 
has two manifestations: one results in a perturbed DNA damage 
response whilst the second impacts upon the regulation of mitotic 
entry. A consideration of the impact of MCPH1 deficiency on the 
DNA damage response is complicated by the finding that different 
results are obtained by MCPH1 siRNA compared to the analysis 
of patient cells. In evaluating findings from patient cell lines, it is 
important to consider whether the mutations are hypomorphic or 
null. As evident from the analysis on NBS cell lines, it can be diffi-
cult to establish whether an apparently null mutation might confer 
residual function.21 Indeed, there may well be strong selection for 
hypomorphic mutations that permit patient viability. Downstream 
Table 1	 An	overview	of	Primary	Microcephaly	and	several	known	DNA	damage	response	disorders
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reinitiation can occur with N-terminal truncating mutations, and 
C-terminal deletions can leave expressed N-terminal fragments. Of 
the two cell lines examined for DNA damage responses, one was 
clearly hypomorphic exhibiting potential for read through of a stop 
codon.4 Since Chk1 and Brca1 are essential, MCPH1 would be 
expected to be essential if it transcriptionally regulates either gene. 
Thus, one possible explanation for the different findings is that 
hypomorphic MCPH1 mutations in the patients confer separation 
of function phenotypes that impact upon some but not all MCPH1 
functions. However, siRNA knock down has the potential to provide 
artefectual results. Distinct MCPH1-specific siRNA oligonucleotides 
gave identical results and transfection with siRNA resistant MCPH1 
cDNA corrected the reduced Chk1/Brca1 expression, rendering it 
unlikely that the impact on Chk1/Brca1 expression can be attribut-
able to off-target siRNA effects. However, significant knock down 
of Chk1/Brca1 following MCPH1 siRNA has not been universally 
observed although elevated PCC formation appears a reproducible 
finding.4,19 Cell line specificity may provide a possible explanation 
for the differing impacts. Impacts on cell cycle progression also need 
to be considered since Brca1 is cell cycle regulated, and MCPH1 
siRNA may perturb cell growth.
Any model for MCPH1 function needs to reconcile the conclu-
sions from these different approaches. A scheme showing the 
differing impacts of MCPH1 deficiency is presented in Figure 2. 
siRNA studies point to an upstream role of MCPH1 in transcrip-
tionally regulating Chk1 and Brca1 (Box 1, Fig. 2). siRNA studies 
Figure 2. Impacts of MCPH1 deficiency. 
One function of MCPH1 (depicted by 
microcephalin‑1 box) suggested by 
siRNA studies is the transcriptional 
regulation of Brca1 and Chk1. A 
second function of MCPH1 (depicted 
by microcephalin‑2 box) suggested 
by siRNA studies is the formation of 
MDC1, 53BP1, p‑ATM and NBS1 
foci. g‑H2AX foci form normally, 
however. Studies on MCPH1 cell 
lines have exposed an MCPH1 func‑
tion that cannot be attributed to an 
impact on Brca1 or Chk1 expression 
in the DNA damage response that 
is downstream of Chk1 activation 
but impacts upon Cdc25A stabili‑
zation (depicted by microcephalin‑3 
box). This could represent a role in 
facilitating Chk1 phosphorylation of 
Cdc25A. MCPH1 can interact with 
Chk1. Finally, MCPH1 has a function 
that does not overlap with the DNA 
damage response in regulating entry 
into mitosis via the regulation of 
Y15‑Cdk1 phosphorylation (depicted 
by microcephalin ‑ 4 box), revealed 
by studies on patient cell lines.
Figure 3. Spindle pole orientation is fundamental 
for normal brain development. Symmetric cell 
division of a shaded progenitor stem cell (A) 
results from cytokinesis along a cleavage plane 
with an apical‑basal orientataion. This generates 
two identical progenitor daughter cells and 
laterally expands the neuroepithelium. 
Asymmetric division (B) occurs upon reorienta‑
tion of the spindle pole, and consequently the 
cleavage plane, generating two cells of different 
developmental fates, a progenitor stem cell and 
a neuron. The neuron then migrates away from 
the ventricular zone, along glial tracks, ultimately 
forming the six‑layered laminar neocortex.
2342 Cell Cycle 2006; Vol. 5 Issue 20
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also suggest a distinct function for MCPH1 in regulating mediator 
protein foci formation (Fig. 2, Box 2). The studies with MCPH1 
cell lines demonstrate a further impact on ATR signalling which 
cannot be attributed to any upstream impact on foci formation or 
Chk1 and Brca1 regulation. These latter studies point to a clinically 
relevant role of MCPH1 in the DNA damage response pathway 
that is downstream of Chk1 activation but impinges upon Cdc25A 
regulation (Fig. 2, Box 3). Since Cdc25A also impacts upon targets 
of the ATM pathway, such as the regulation of Cdc45 following 
DSBs in S phase cells which regulates the initiation of replication, it 
is possible that MCPH1 cell lines will show impaired ATM signal-
ling, although normal �2/M checkpoint arrest was observed in one 
study.17 MCPH1 could impact upon Cdc25A regulation by acting 
as a mediator protein to facilitate its phosphorylation by Chk1 
and/or Chk2 . Alternatively, MCPH1 could regulate proteins that 
themselves regulate Cdc25A phosphorylation including the 
Wee1-Myt1 kinases. It is also possible that MCPH1 could impart 
an impact via regulation of ubiquitin-mediated degradation of 
Cdc25A. Currently, it is not known whether MCPH1 also impacts 
upon the phosphorylation of Cdc25B and C, which function coop-
eratively with Cdc25A to control cell cycle regulation although 
details of the interplay between these three phosphatases is still 
poorly understood.18 Finally, the cellular studies have also identi-
fied an MCPH1 function in unperturbed cell cycle regulation that 
is distinct from any role in ATR signalling (Fig. 2, Box 4), which 
represents a highly important finding. Indeed, the PCC pheno-
type is a characteristic feature of all MCPH1 cell lines, which is 
recapitulated by siRNA studies. The evidence suggests that MCPH1 
regulates the levels of pY15-Cdk1, either by promoting phosphor-
ylation or enhancing dephosphorylation. A consequence of reduced 
pY15-Cdk1 appears to be premature chromosome condensation 
caused in part by untimely localisation of condensin II. Recent 
studies have argued that ATR-dependent signalling regulates unper-
turbed cell cycle progression as well as after DNA damage.22 It is 
important to realise, however, that neither ATR-Seckel nor A-T cell 
lines display the PCC phenotype characteristic of MCPH1 cell lines, 
although MCPH1 cell lines show similar defects in ATR-signalling 
responses to ATR-Seckel cells.4 Thus, the evidence suggests that 
MCPH1 has an important role in regulating mitotic entry that is 
distinct to its role in the DNA damage response.
centrOsOMes, Atr AnD MicrOcePhAly
The analysis of patient cell lines has the advantage that it allows the 
cellular analysis to be linked to clinical features. MCPH1 is, to date, 
the only characterised protein defective in Primary Microcephaly 
patients that has a role in the DNA damage response. MCPH1 
patients, in contrast to other Primary Microcephaly patients, 
display reduced stature, a characteristic shared with conditions 
exhibiting defective ATR-signalling (ATR-Seckel and NBS). This, 
the growth delay seen in MCPH1 patients may be a consequence 
of ATR-signalling defects. In contrast, microcephaly is a feature 
observed in ATR-SS as well as all Primary Microcephaly patients. 
Another feature observed in MCPH1 and ATR-SS cell lines is the 
presence of mitotic cells with supernumerary centrosomes, which 
can represent up to 30 % of the cells within a population, suggesting 
that ATR via MCPH1 may regulate centrosome stability.4 Strikingly, 
defects in coordinating microtubule nucleation at centrosomes or 
other defects affecting centrosomal biogenesis have been observed 
in other Primary Microcephaly patients or cell lines from them.23 
Cerebrocortical development is achieved via a highly regulated 
sequence of neural progenitor cell division, migration and differen-
tiation (Fig. 3). Neuroprogenitor cells form in the neuroepithelium 
of the ventricular zone around the ventricles of the developing brain 
where they symmetrically divide generating more progenitor cells in 
a lateral expansion (Fig. 3A). Each of these progenitor cells under-
goes asymmetric cell division by altering the cleavage plane from the 
apical to basal orientation by repositioning the spindle pole, creating 
a daughter progenitor stem cell and a neuron (Fig. 3B). The neuronal 
cells migrate from the ventricles along radial glia tracks undergoing 
terminal differentiation ultimately forming a six-layered laminar 
neocortex. Therefore, spindle pole orientation is a critical determinant 
of normal brain development. It is anticipated, therefore, that brain 
development might be highly sensitive to any perturbation in the 
maintenance of centrosome stability and function.24 Recently, 
Abnormal Spindle in mammalian (Aspm, the MCPH5 locus, Table1) 
has been shown to be essential in maintaining cleavage plan orienta-
tion that allows symmetric cell division.25 Therefore, centrosome 
stability and correct spindle pole orientation potentially represent an 
‘Achilles heel’ in brain growth during development.
Table 2	 A	clinical	comparison	between	Primary	Microcephaly		to	known	DNA	damage	response	disorders
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cOnclusiOns
In conclusion, recent studies have provided important insight 
into the function of MCPH1, a protein that is critical for normal 
brain development. Although data from the analysis of patient 
cell lines and siRNA approaches are somewhat confusing and 
apparently discrepant, there is mounting evidence that MCPH1 
is a damage response protein that functions to ensure efficient cell 
cycle checkpoint arrest after DNA damage. In distinction to this 
response, and probably as importantly, MCPH1 functions to regu-
late timely mitotic entry. As a consequence, cell lines from MCPH1 
patients have abnormal �2-like cells which have inappropriately 
commenced premature condensation yet not progressed normally 
into mitosis. MCPH1 thus appears to be a protein that functions at 
the gateway of cell cycle regulation and its interface with the DNA 
damage response, and we await further studies to reveal the precise 
point(s) at which this fascinating protein functions.
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